Noted: Some provisions in the working group’s wide-ranging plan, which it presented at a meeting of the NIH’s Advisory Committee to the Director (ACD) in Bethesda, Maryland, are already proving controversial. For example, the panel recommends asking grant recipients about their conduct over the previous seven years. But panel members “weren’t able to answer how or why” they settled on a seven-year window, says Juan Pablo Ruiz, a stem-cell biologist at the University of Wisconsin-Madison.